FIELD: medicine.
SUBSTANCE: discloses an injectable pharmaceutical composition for the treatment of a pathological condition of the liver, containing: (a) 25 mg/ml of ursodeoxycholic acid and (b) from 179 mg/ml to 248 mg/ml of sulfobutyl ether -β -cyclodextrin (variants).
EFFECT: providing a composition based on ursodeoxycholic acid suitable for intravenous administration, which is stable under environmental and/or cooling conditions, characterized by a significantly reduced volume for intravenous administration, and providing completely dissolved ursodeoxycholic acid without the need to use large amounts of strong bases.
5 cl, 3 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS WHICH CONTAIN EPOTHILONE, AND METHOD OF THEIR OBTAINING | 2005 |
|
RU2416407C2 |
| PARENTERAL LIQUID PREPARATION INCLUDING CARBAMATE COMPOUND | 2017 |
|
RU2761041C2 |
| COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR, COMPOSITION OF RAS-FARNESYLT RANSFERASE INHIBITOR, PHARMACEUTICAL COMPOSITION | 1999 |
|
RU2230062C2 |
| FORMULATIONS OF INTRAVENOUS SOLUTIONS OF POSACONAZOLE STABILISED BY SUBSTITUTED BETA-CYCLODEXTRINE | 2011 |
|
RU2575768C2 |
| AQUEOUS COMPOSITION CONTAINING DANTROLENE | 2016 |
|
RU2729043C2 |
| COMPOSITION OF BCL-2 INHIBITOR BASED ON CYCLODEXTRIN | 2019 |
|
RU2804366C2 |
| METHODS OF TREATMENT OF EPILEPSY OR STATUS EPILEPTICUS | 2013 |
|
RU2824132C2 |
| METHODS OF TREATMENT OF EPILEPSY OR STATUS EPILEPTICUS | 2013 |
|
RU2667010C2 |
| BENDAMUSTINE AND CYCLOPOLYSACCHARIDE COMPOSITIONS | 2010 |
|
RU2734236C2 |
| STABILISED VORICONAZOLE COMPOSITION | 2011 |
|
RU2566262C2 |
